$基石药业-B(02616)$ 市场还是低估了舒格利单抗和Ewopharma就中东欧及瑞士的合作协议的利好了。从这个合作看，舒格利这一个药就值现在的15亿市值了。而且5130万美元的预付款到账，基石的现金流是肯定没有问题的，按照公司说法，其他地区的舒格利合作也在深入探讨中，既然是深入探讨，说明已经接近谈成。
低估，太低估了。
下述是Ewopharma官网上的新闻公告网页链接。
这是百度翻译的结果，所以也不能说基石的公告错误诱导。有一种可能是Ewopharma为了取得一个好价格，所以给了基石满意的预付款。也有可能是买了多少药的预付款。预付款还是有好多种解释的，具体是哪一种情况只有他们两家知道了。不管是哪一种解释，说明舒格利是个好药，基石市值市场低估了，后面还是会纠偏的。继续耐心持有，等到解套、赚钱的那一天。
根据协议条款，CStone将获得高达5130万美元的预付款，以及在实现某些监管和销售里程碑后应支付的额外对价。此外，CStone将从对Ewopharma及其附属公司的供应销售中获得收入。Ewopharma将负责定价、报销、销售和营销以及分销，而CStone将负责产品供应，并为品牌提供必要的培训和支持。
CStone will receive up to $51.3 million in upfront payment and additional considerations payable upon the achievement of certain regulatory and sales milestones.
CStone will book international revenues via the sale of supply to Ewopharma.
下述是Ewopharma官网上的新闻公告全文。
The European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) are reviewing the marketing authorization application (MAA) for sugemalimab in combination with chemotherapy as the first-line treatment of metastatic non-small cell lung cancer.
从设个条款看，Ewopharma就是一个在中东欧及瑞士的独家经销商。
Schaffhausen, Switzerland, 27th May 2024 – Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). These include EU member countries Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia, as well as non-EU countries Albania, Bosnia & Herzegovina, Kosovo, North Macedonia, Moldova, Montenegro, Serbia.
The partnership will maximize the value of sugemalimab (anti-PD-L1 monoclonal antibody) in Central Eastern Europe and Switzerland.CStone will receive up to $51.3 million in upfront payment and additional considerations payable upon the achievement of certain regulatory and sales milestones.CStone will book international revenues via the sale of supply to Ewopharma.The European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) are reviewing the marketing authorization application (MAA) for sugemalimab in combination with chemotherapy as the first-line treatment of metastatic non-small cell lung cancer.
Under the terms of the agreement, CStone will receive up to $51.3 million in upfront payment and additional considerations payable upon the achievement of certain regulatory and sales milestones. In addition, CStone will book revenues from sales of supply to Ewopharma and its affiliates. Ewopharma will be in charge of pricing, reimbursement, sales & marketing, and distribution, whilst CStone will be responsible for product supply and provide necessary training and support for the brand.
Dr. Jason Yang, CEO and President of R&D at CStone, said: “As a potentially best-in-class anti-PD-L1 monoclonal antibody, sugemalimab has demonstrated remarkable efficacy in multiple clinical trials and has already been approved in China for five indications, covering stage III and IV NSCLC, gastric cancer, esophageal squamous carcinoma, and extranodal NK/T-cell lymphoma. In European markets, we look forward to receiving MAA approval from the European Medicines Agency in the near future. We believe sugemalimab has a broad application prospect in Europe and global markets. Ewopharma is a reliable pharmaceutical marketing partner with abundant experience and extensive channels in CEE markets. The collaboration will undoubtedly help sugemalimab maximize its clinical and commercial value and benefit more patients in Europe. We look forward to taking a firm step toward the international commercialization of sugemalimab with Ewopharma.”
Alain Staub, CEO and Chairman of the Board of Ewopharma adds: “We are delighted to enter into this strategic partnership with CStone. Sugemalimab is an innovative treatment further expanding our oncology franchise and allows us to make an important contribution to health
equity in our region. According to Globocan 2022, lung cancer is the third most common cancer in Europe and the leading cause of cancer-related deaths, accounting for one-fifth of all cancer deaths. Sugemalimab will improve the treatment landscape for patients with advanced non-small cell lung cancer. We are very happy to be able to bring hope and optimism to patients and healthcare professionals alike.”
Sugemalimab, an anti-PD-L1 monoclonal antibody developed by CStone, has been granted approvals in China for all five indications that entered late-stage clinical trials, including stage III and IV NSCLC, extranodal NK/T-cell lymphoma, esophageal squamous carcinoma, and gastric cancer. EMA and UK MHRA are reviewing the MAA for sugemalimab in combination with chemotherapy as the first-line treatment of metastatic NSCLC.
The clinical data of sugemalimab have been presented at various international academic conferences and published in top-tier journals such as The Lancet Oncology, Nature Medicine, Nature Cancer, and Journal of Clinical Oncology. CStone is also in discussions with regulatory authorities including EMA, UK MHRA, and US Food and Drug Administration (FDA) for other indications of sugemalimab and actively expanding partnerships for development and commercialization in other regions worldwide.
About Ewopharma AG
Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a pharmaceutical marketing company focused on Central Eastern Europe and Switzerland. With more than 60 years presence in the region, Ewopharma has extensive knowledge of these markets and enjoys a privileged position in the area. The company covers all aspects of market access and commercialization of ethical pharmaceutical and consumer health products. Further information is available at www.ewopharma.com.
PR contact: r.schaberl@ewopharma.com
About CStone
CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the company has made significant strides since its inception. To date, the company has successfully launched four innovative drugs and secured approvals for 14 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 12 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.
PR contact: pr@cstonepharma.com
IR contact: ir@cstonepharma.com
Ewopharma公司介绍
Ewopharma is the successor company to M.R. Leclerc & Co., founded in 1959. From the start, our focus has been on building bridges to the pharmaceutical markets of Central Eastern Europe. Much has changed in the region since 1959 – both economically and politically – and over this period we have gained an in-depth understanding of the markets and an esteemed standing there.
While we started purely as a marketing partner for pharmaceutical companies, we have since acquired and launched proprietary products. Our brand Revalid® - a product line for holistic hair care and hair loss treatment - was developed in 1992 in Switzerland. In 2011, we acquired Irish healthcare company Newport Pharmaceuticals Ltd. giving us full ownership of the antiviral drug Isoprinosine® in the same year. Overseen by our head office in Schaffhausen, Switzerland, we now channel our industry knowledge and experience into the successful placement of both Ewopharma and partner brands in our target markets. In 2004, we joined the RX-Alliance, a professional cooperation network of successful pharmaceutical companies active in selected European markets.